<span item_type="fundamental" item_id="a9b7c1b95dbc74d817d77b3455f33628" counter_id="ST/US/CKPT" env="prod"></span><span item_type="announcement" item_id="515747617887687937" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.19.</p><p></p><h3>Cash Position</h3><ul><li>As of March 31, 2025, Checkpoint Therapeutics, Inc.’s cash and cash equivalents totaled $33.0 million, compared to $6.6 million at December 31, 2024, reflecting an increase of $26.4 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000110465925047867/tm2514952d1_ex99-1.htm"></span></li></ul><h3>Research and Development (R&amp;D) Expenses</h3><ul><li>R&amp;D expenses for the first quarter of 2025 were $3.8 million, a decrease from $8.5 million in the first quarter of 2024, representing a reduction of $4.7 million. The R&amp;D expenses for the first quarter of 2025 included $0.7 million of non-cash stock expenses, compared to $0.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000110465925047867/tm2514952d1_ex99-1.htm"></span></li></ul><h3>General and Administrative (G&amp;A) Expenses</h3><ul><li>G&amp;A expenses for the first quarter of 2025 were $7.4 million, an increase from $2.5 million in the first quarter of 2024, marking an increase of $4.9 million. The G&amp;A expenses for the first quarter of 2025 included $1.3 million of non-cash stock expenses, compared to $0.6 million for the first quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000110465925047867/tm2514952d1_ex99-1.htm"></span></li></ul><h3>Net Loss</h3><ul><li>The net loss attributable to common stockholders for the first quarter of 2025 was $11.2 million, or $0.19 per share, compared to a net loss of $10.9 million, or $0.33 per share, in the first quarter of 2024. The net loss for the first quarter of 2025 included $2.0 million of non-cash stock expenses, compared to $1.1 million for the first quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000110465925047867/tm2514952d1_ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>The merger with Sun Pharmaceutical Industries, Inc. is expected to be completed in the second quarter of 2025, subject to customary closing conditions and regulatory approvals. The total transaction value, including the upfront cash payment and the maximum value of the contingent value right, is up to approximately $416 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000110465925047867/tm2514952d1_ex99-1.htm"></span></li></ul>

Checkpoint Therap | 8-K: FY2025 Q1 EPS: USD -0.19